Vertex Pharmaceuticals Incorporated Raises Price Target Following Encouraging Phase 3 Trial Results for IgAN Treatment.

Truist Securities raised its price target for Vertex Pharmaceuticals to $525 from $490, citing encouraging Phase 3 trial results for its IgAN treatment. The trial satisfied all primary and secondary objectives and demonstrated a strong safety profile. However, Stifel remains uncertain about the medication's competitiveness in the saturated IgAN market. Vertex Pharmaceuticals is a global biotechnology company focused on cystic fibrosis and genetic disorders.